Researcher
Davie Cappoen
- Keywords:Chemistry (incl. biochemistry)
- Disciplines:Analytical chemistry, Inorganic chemistry, Macromolecular and materials chemistry, Medicinal and biomolecular chemistry, Organic chemistry, Physical chemistry, Sustainable chemistry, Theoretical and computational chemistry, Other chemical sciences, Biochemistry and metabolism, Other biological sciences, Other natural sciences
Affiliations
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Member
From1 Apr 2014 → 14 Nov 2022
Projects
1 - 9 of 9
- RNA biomarkers discovery for ultra-fast drug synergy and susceptibility testing in the mycobacterium avium complex.From1 Jan 2020 → 31 Oct 2020Funding: BOF - doctoral mandates
- Towards the realization of a structural biology platform at the University of Antwerp: The Mosquito Xtal3 crystallization robot as the missing link.From1 Jan 2020 → 31 Dec 2021Funding: BOF - scientific equipment program
- Exploitation of key enzymes of the mycothiol biosynthesis to improve treatment of mycobacterium avium complex infections.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).From1 May 2019 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Development of a comprehensive platform for targeting redox homeostasis in Mycobacterium tuberculosis.From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Nanobody-assisted targeting of sialoadhesin-positive macrophages to improve the treatment of tuberculosis.From1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
- Elucidation of the octahydrobenzo[j]phenantridinediones as putitive redox cyclers in Mycobacterium tuberculosis.From1 Apr 2016 → 31 Mar 2017Funding: BOF - Other initiatives
- Biological evaluation of 1,3-diaryltriazenes and their mechanism of action on Mycobacterium tuberculosis.From1 Feb 2016 → 5 Jan 2020Funding: FWO Strategic Basic Research Grant
- Elucidating the mechanism of action of octahydrobenzo[j] phenanthridinediones as novel potent antimycobacterialcompounds.From1 Oct 2014 → 30 Sep 2017Funding: FWO fellowships
Publications
21 - 30 of 41
- Design, Synthesis and Biological Evaluation of Novel Tetrahydroquinoline Based Propanehydrazides as Antitubercular Agents(2017)
Authors: Subhash Chander, Penta Ashok, Bidart Macedo de Maira, Paul Cos, Davie Cappoen, Sankaranarayanan Murugesan
Pages: 293 - 300 - Monoclonal antibody binding to the macrophage-specific receptor sialoadhesin alters the phagocytic properties of human and mouse macrophages(2017)
Authors: Marjorie De Schryver, Davie Cappoen, Dirk Elewaut, Hans J. Nauwynck, Louis Maes, Guy Caljon, Paul Cos, Peter Delputte
Pages: 51 - 60 - Comparative analysis of the internalization of the macrophagereceptor sialoadhesin in human and mouse primary macrophages andcell lines(2017)
Authors: Marjorie De Schryver, Annelies Leemans, Isabel Pintelon, Davie Cappoen, Louis Maes, Guy Caljon, Paul Cos, Peter Delputte
Pages: 797 - 806 - Phytochemical and in vitro antimicrobial and genotoxic activity in the brown algae Dictyopteris membranacea(2017)
Authors: N. Akremi, Davie Cappoen, R. Anthonissen, Luc Verschaeve, A. Bouraoui
Pages: 308 - 314 - Evaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models(2017)
Authors: Freija Van den Driessche, Bieke Vanhoutte, Gilles Brackman, Aurélie Crabbé, Petra Rigole, Jurgen Vercruysse, Glenn Verstraete, Davie Cappoen, Chris Vervaet, Paul Cos, et al.
- Optimization and characterization of a murine lung infection model for the evaluation of novel therapeutics against Burkholderia cenocepacia(2017)
Authors: Bieke Vanhoutte, Davie Cappoen, Maira Bidart de Macedo, Freya Cools, Eveline Torfs, Tom Coenye, Wim Martinet, Guy Caljon, Louis Maes, Peter Delputte, et al.
Pages: 181 - 188 - Design, synthesis and antitubercular potency of 4-hydroxyquinolin-2(1H)-ones(2017)
Authors: Maira Bidart de Macedo, Roman Kimmel, Damijana Urankar, Martin Gazvoda, Antonio Peixoto, Freya Cools, Eveline Torfs, Luc Verschaeve, Emerson Silva Lima, Antonin Lycka, et al.
Pages: 491 - 500 - Novel potentiators for vancomycin in the treatment of biofilm-related MRSA infections via a mix and match approach(2017)
Authors: Arno Vermote, Gilles Brackman, Martijn D.P. Risseeuw, Davie Cappoen, Paul Cos, Tom Coenye, Serge Van Calenbergh
Pages: 38 - 42 - Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents(2016)
Authors: Lijun Song, Martijn D. P. Risseeuw, Matheus Froeyen, Izet Karalic, Jan Goeman, Davie Cappoen, Johan Van der Eycken, Paul Cos, Helene Munier-Lehmanne, Serge Van Calenbergh
Pages: 5172 - 5182 - Synthesis and anti-tubercular activity of $N^{2}$-arylbenzo[g]isoquinoline-5,10-dione-3-iminium bromides(2016)
Authors: Gertjan Rotthier, Davie Cappoen, Quang Trung Nguyen, Tuyet Anh Dang Thi, V. Mathys, Van Tuyen Nguyen, K. Huygen, Paul Cos
Pages: 2041 - 2051